Rezolute Inc (RZLT)

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as...

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the...

Form 8-K - Current report

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the...

Form 8-K - Current report

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate...

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data...

Form 8-K - Current report

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the...

Form 4 - Statement of changes in beneficial ownership of securities